Research Analysts Set Expectations for BOLT Q3 Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Bolt Biotherapeutics in a research report issued on Monday, October 20th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($5.05) for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q4 2025 earnings at ($4.93) EPS and FY2026 earnings at ($17.96) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($4.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.40) by $1.94. The firm had revenue of $1.80 million during the quarter, compared to analysts’ expectations of $0.82 million.

Several other equities research analysts have also commented on the stock. Lake Street Capital boosted their target price on shares of Bolt Biotherapeutics to $75.00 and gave the stock a “buy” rating in a research report on Friday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $34.00.

Bolt Biotherapeutics Stock Performance

NASDAQ:BOLT opened at $5.75 on Wednesday. The firm’s fifty day moving average price is $5.39 and its 200 day moving average price is $6.00. Bolt Biotherapeutics has a 1-year low of $4.59 and a 1-year high of $14.36. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.11 and a quick ratio of 3.11. The firm has a market cap of $11.03 million, a price-to-earnings ratio of -0.22 and a beta of 0.91.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.